Legal Proceedings
−Removed: In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its Chief Executive Officer.
−Removed: The complaint, later amended to add our Chief Financial Officer as a defendant, which purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, alleges material misstatements and/or omissions in the Company’s public statements with respect to the results from its phase 3 LUNAR clinical trial.
+Added: In June 2023, a putative class action lawsuit was filed against the Company, its Executive Chairman and its former Chief Executive Officer.
+Added: The complaint, later amended to add our former Chief Financial Officer as a defendant, which purports to be brought on behalf of a class of persons and/or entities who purchased or otherwise acquired ordinary shares of the Company from January 5, 2023 through June 5, 2023, alleges material misstatements and/or omissions in the Company’s public statements with respect to the results from its phase 3 LUNAR clinical trial.
+Added: On March 18, 2025, the court granted the Company's motion to dismiss the complaint.
+Added: The Plaintiffs have until May 8, 2025 to appeal the court's ruling.
The Company believes that the action is without merit and plans to defend the lawsuit vigorously.
9 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.